Baird Starts CRISPR Therapeutics (CRSP) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CRSP Hot Sheet
Price: $51.78 +3.58%
Rating Summary:
19 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
19 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Baird analyst Jack Allen initiates coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Neutral rating and a price target of $46.00.
For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.
Shares of CRISPR Therapeutics closed at $50.84 yesterday.
You May Also Be Interested In
- CRISPR Therapeutics (CRSP) PT Lowered to $70 at Wells Fargo
- CRISPR Therapeutics (CRSP) Reiterated at Market Outperform by Citizens on Robust CASGEVY Patient Pipeline
- Bernstein SocGen Group Starts Abbott India Ltd (BOOT:IN) at Market Perform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
